David Cherney1,2, Søren S Lund3, Bruce A Perkins4, Per-Henrik Groop5,6,7, Mark E Cooper7, Stefan Kaspers3, Egon Pfarr3, Hans J Woerle3, Maximilian von Eynatten3. 1. Toronto General Hospital, 585 University Ave, 8N-845, Toronto, ON, Canada, M5G 2N2. david.cherney@uhn.ca. 2. Department of Medicine, Division of Nephrology, and Department of Physiology, University of Toronto, Toronto, ON, Canada. david.cherney@uhn.ca. 3. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany. 4. Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. 5. Abdominal Centre Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 6. Folkhälsan Research Centre, Biomedicum Helsinki, Helsinki, Finland. 7. Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
Abstract
AIMS/HYPOTHESIS: Sodium glucose cotransporter 2 (SGLT2) inhibition lowers HbA1c, systolic BP (SBP) and weight in patients with type 2 diabetes and reduces renal hyperfiltration associated with type 1 diabetes, suggesting decreased intraglomerular hypertension. As lowering HbA1c, SBP, weight and intraglomerular pressure is associated with anti-albuminuric effects in diabetes, we hypothesised that SGLT2 inhibition would reduce the urine albumin-to-creatinine ratio (UACR) to a clinically meaningful extent. METHODS: We examined the effect of the SGLT2 inhibitor empagliflozin on UACR by pooling data from patients with type 2 diabetes and prevalent microalbuminuria (UACR = 30-300 mg/g; n = 636) or macroalbuminuria (UACR > 300 mg/g; n = 215) who participated in one of five phase III randomised clinical trials. Primary assessment was defined as percentage change in geometric mean UACR from baseline to week 24. RESULTS: After controlling for clinical confounders including baseline log-transformed UACR, HbA1c, SBP and estimated GFR (according to the Modification of Diet in Renal Disease [MDRD] formula), treatment with empagliflozin significantly reduced UACR in patients with microalbuminuria (-32% vs placebo; p < 0.001) or macroalbuminuria (-41% vs placebo; p < 0.001). Intriguingly, in regression models, most of the UACR-lowering effect with empagliflozin was not explained by SGLT2 inhibition-related improvements in HbA1c, SBP or weight. CONCLUSIONS/ INTERPRETATION: In patients with type 2 diabetes and either micro- or macroalbuminuria, empagliflozin reduced UACR by a clinically meaningful amount. This effect was largely independent of the known metabolic or systemic haemodynamic effects of this drug class. Our results further support a direct renal effect of SGLT2 inhibitors. Prospective studies are needed to explore the potential of this intervention to alter the course of kidney disease in high-risk patients with diabetes. TRIAL REGISTRATION: Clinicaltrials.gov NCT01177813 (study 1); NCT01159600 (study 2); NCT01159600 (study 3); NCT01210001 (study 4); and NCT01164501 (study 5).
RCT Entities:
AIMS/HYPOTHESIS: Sodium glucose cotransporter 2 (SGLT2) inhibition lowers HbA1c, systolic BP (SBP) and weight in patients with type 2 diabetes and reduces renal hyperfiltration associated with type 1 diabetes, suggesting decreased intraglomerular hypertension. As lowering HbA1c, SBP, weight and intraglomerular pressure is associated with anti-albuminuric effects in diabetes, we hypothesised that SGLT2 inhibition would reduce the urine albumin-to-creatinine ratio (UACR) to a clinically meaningful extent. METHODS: We examined the effect of the SGLT2 inhibitor empagliflozin on UACR by pooling data from patients with type 2 diabetes and prevalent microalbuminuria (UACR = 30-300 mg/g; n = 636) or macroalbuminuria (UACR > 300 mg/g; n = 215) who participated in one of five phase III randomised clinical trials. Primary assessment was defined as percentage change in geometric mean UACR from baseline to week 24. RESULTS: After controlling for clinical confounders including baseline log-transformed UACR, HbA1c, SBP and estimated GFR (according to the Modification of Diet in Renal Disease [MDRD] formula), treatment with empagliflozin significantly reduced UACR in patients with microalbuminuria (-32% vs placebo; p < 0.001) or macroalbuminuria (-41% vs placebo; p < 0.001). Intriguingly, in regression models, most of the UACR-lowering effect with empagliflozin was not explained by SGLT2 inhibition-related improvements in HbA1c, SBP or weight. CONCLUSIONS/ INTERPRETATION: In patients with type 2 diabetes and either micro- or macroalbuminuria, empagliflozin reduced UACR by a clinically meaningful amount. This effect was largely independent of the known metabolic or systemic haemodynamic effects of this drug class. Our results further support a direct renal effect of SGLT2 inhibitors. Prospective studies are needed to explore the potential of this intervention to alter the course of kidney disease in high-risk patients with diabetes. TRIAL REGISTRATION: Clinicaltrials.gov NCT01177813 (study 1); NCT01159600 (study 2); NCT01159600 (study 3); NCT01210001 (study 4); and NCT01164501 (study 5).
Entities:
Keywords:
Empagliflozin; Macroalbuminuria; Microalbuminuria; Sodium glucose cotransporter 2; Type 2 diabetes; Urine albumin-to-creatinine ratio
Authors: Scott C Thomson; Timo Rieg; Cynthia Miracle; Hadi Mansoury; Jean Whaley; Volker Vallon; Prabhleen Singh Journal: Am J Physiol Regul Integr Comp Physiol Date: 2011-09-21 Impact factor: 3.619
Authors: Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress Journal: Lancet Date: 2010-11-06 Impact factor: 79.321
Authors: Mark E Cooper; Vlado Perkovic; Janet B McGill; Per-Henrik Groop; Christoph Wanner; Julio Rosenstock; Uwe Hehnke; Hans-Juergen Woerle; Maximilian von Eynatten Journal: Am J Kidney Dis Date: 2015-05-07 Impact factor: 8.860
Authors: Volker Vallon; Maria Gerasimova; Michael A Rose; Takahiro Masuda; Joseph Satriano; Eric Mayoux; Hermann Koepsell; Scott C Thomson; Timo Rieg Journal: Am J Physiol Renal Physiol Date: 2013-11-13
Authors: David Zi Cherney; Bruce A Perkins; Nima Soleymanlou; Ronnie Har; Nora Fagan; Odd Erik Johansen; Hans-Juergen Woerle; Maximilian von Eynatten; Uli C Broedl Journal: Cardiovasc Diabetol Date: 2014-01-29 Impact factor: 9.951
Authors: Hans-Ulrich Häring; Ludwig Merker; Elke Seewaldt-Becker; Marc Weimer; Thomas Meinicke; Hans J Woerle; Uli C Broedl Journal: Diabetes Care Date: 2013-08-20 Impact factor: 19.112
Authors: David León Jiménez; David Z I Cherney; Petter Bjornstad; Luis Castilla-Guerra; José Pablo Miramontes González Journal: Am J Physiol Renal Physiol Date: 2018-08-01
Authors: Harindra Rajasekeran; Heather N Reich; Michelle A Hladunewich; Daniel Cattran; Julie A Lovshin; Yuliya Lytvyn; Petter Bjornstad; Vesta Lai; Josephine Tse; Leslie Cham; Syamantak Majumder; Bridgit B Bowskill; M Golam Kabir; Suzanne L Advani; Ian W Gibson; Manish M Sood; Andrew Advani; David Z I Cherney Journal: Am J Physiol Renal Physiol Date: 2017-11-15
Authors: Christoph Wanner; Hiddo J L Heerspink; Bernard Zinman; Silvio E Inzucchi; Audrey Koitka-Weber; Michaela Mattheus; Stefan Hantel; Hans-Juergen Woerle; Uli C Broedl; Maximilian von Eynatten; Per-Henrik Groop Journal: J Am Soc Nephrol Date: 2018-10-12 Impact factor: 10.121
Authors: Maarten A de Jong; Sergei I Petrykiv; Gozewijn D Laverman; Antonius E van Herwaarden; Dick de Zeeuw; Stephan J L Bakker; Hiddo J L Heerspink; Martin H de Borst Journal: Clin J Am Soc Nephrol Date: 2018-12-17 Impact factor: 8.237
Authors: Yuliya Lytvyn; Petter Bjornstad; Daniel H van Raalte; Hiddo L Heerspink; David Z I Cherney Journal: Endocr Rev Date: 2020-04-01 Impact factor: 19.871
Authors: Vikas Srinivasan Sridhar; Jaya Prakash N Ambinathan; Matthias Kretzler; Laura L Pyle; Petter Bjornstad; Sean Eddy; David Z Cherney; Heather N Reich Journal: Am J Physiol Renal Physiol Date: 2019-09-23